Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 10/20 | 0.58 |
| ▸ | NMUR1 | Q9HB89 | 10/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | APLNR | P35414 | 1/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.52 |
| ▸ | CALCR | P30988 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350217 | 0.96 | NMUR2 (0.58) | NMUR2NMUR1EPHA2KISS1R | |
| SCHEMBL29788968 | 0.90 | NMUR2 (0.60) | NMUR2NMUR1 | |
| SCHEMBL31433229 | 0.89 | MAPK8 (0.58) | NMUR2NMUR1MAPK8MAPK9MAPK10 | |
| SCHEMBL31679323 | 0.89 | OPRM1 (0.56) | EPHA2APLNR | |
| SCHEMBL29639695 | 0.88 | NMUR2 (0.51) | NMUR2NMUR1EPHA2APLNRKISS1R | |
| SCHEMBL31679332 | 0.87 | MAPK8 (0.60) | MAPK8MAPK9MAPK10APLNRCALCR | |
| SCHEMBL31433244 | 0.87 | APLNR (0.58) | NMUR2NMUR1MAPK8MAPK9MAPK10 | |
| SCHEMBL31473044 | 0.86 | NMUR2 (0.58) | NMUR2NMUR1EPHA2MAPK8MAPK9 | |
| SCHEMBL31307220 | 0.85 | NMUR2 (0.60) | NMUR2NMUR1 | |
| SCHEMBL30524356 | 0.85 | OPRM1 (0.58) | NMUR2NMUR1APLNRNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759509-B2 | WT1 antigen peptide conjugate vaccine | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-19 | — | — | US | disclosed |
| EP-3199175-B1 | PHARMACEUTICAL COMPOSITION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759509-B2 | WT1 antigen peptide conjugate vaccine | MICA, HLA-DRB1, HLA-B | NMUR2 3362/4885NMUR1 2617/4885EPHA2 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.